Zealand Pharma A/S (OTCMKTS:ZLDPF) Short Interest Down 63.8% in June

Zealand Pharma A/S (OTCMKTS:ZLDPF) saw a large drop in short interest in the month of June. As of June 15th, there was short interest totaling 374,424 shares, a drop of 63.8% from the May 31st total of 1,035,563 shares. Approximately 0.5% of the company’s shares are short sold. Based on an average daily trading volume, of 4,924 shares, the short-interest ratio is presently 76.0 days.

Zealand Pharma A/S Price Performance

Shares of ZLDPF stock opened at $42.89 on Monday. Zealand Pharma A/S has a fifty-two week low of $35.93 and a fifty-two week high of $83.12. The company has a debt-to-equity ratio of 0.02, a quick ratio of 37.17 and a current ratio of 37.17. The firm has a market capitalization of $3.07 billion, a price-to-earnings ratio of 3.18 and a beta of 0.86. The stock’s 50-day simple moving average is $47.67 and its 200-day simple moving average is $55.51.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its earnings results on Thursday, May 7th. The company reported ($0.87) EPS for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.50. Zealand Pharma A/S had a return on equity of 41.80% and a net margin of 68.82%.The firm had revenue of $5.33 million for the quarter, compared to analyst estimates of $2.81 million. As a group, equities analysts forecast that Zealand Pharma A/S will post 2.37 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Berenberg Bank lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. BNP Paribas Exane cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. Finally, Wolfe Research downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. Three analysts have rated the stock with a Strong Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, Zealand Pharma A/S has an average rating of “Moderate Buy”.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.